clinical trial · NCT06966284
A Post-Marketing Study to Assess the Efficacy and Safety of Intravenous Polymyxin B and Colistin Methanesulfonate in Patients With Carbapenem-Resistant Gram-Negative Bacterial Infection
TTY Biopharm·—·recruiting·n = 480
Bacteremia Caused by Gram-Negative BacteriaBacterial Pneumonia
brief summary
This is a retrospective, observational, post-marketing study to evaluate the clinical response, microbiological response, mortality, and safety of intravenous polymyxin B and colistin methanesulfonate in patients with carbapenem-resistant gram-negative bacterial infection. Subgroup analysis by sites of infection, infectious pathogens, and baseline renal function will also be performed.
started
Nov 26, 2025
primary completion
Nov 30, 2028
completion
Nov 30, 2028
last updated
Mar 9, 2026
official title
A Retrospective, Observational, Post-Marketing Study to Assess the Efficacy and Safety of Intravenous Infusions Polymyxin B and Colistin Methanesulfonate in Patients With Carbapenem-Resistant Gram-Negative Bacterial Infection
sourced from ClinicalTrials.gov · pharmadog mirrors structured fields, not the full protocol